Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Tillu, Girish
- Reverse Pharmacology Effectuated by Studies of Ayurvedic Products for Arthritis
Abstract Views :251 |
PDF Views:82
Authors
Affiliations
1 Medical Research Centre, Kasturba Health Society, K. Desai Road, Vile-Parle (W), Mumbai 400 056, IN
2 Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Ganeshkhind, Pune 411 007, IN
1 Medical Research Centre, Kasturba Health Society, K. Desai Road, Vile-Parle (W), Mumbai 400 056, IN
2 Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Ganeshkhind, Pune 411 007, IN
Source
Current Science, Vol 111, No 2 (2016), Pagination: 337-342Abstract
Reverse pharmacology (RP) is a trans-disciplinary path for drug discovery and development from bedside observations on drug effects to bench-side experiments. This approach generates evidence of safety and efficacy at different levels of biological organization, ranging from cell to community. Eventually the innovative integration of research methods will be translated back to the bedside as a new drug. The experiential wisdom of traditional systems like Ayurveda is scientifically explored by systematic RP. This is meant to enrich modern medicine, by the relevant application of the drug discovery sciences. The evidence by RP would also help to rationally understand Ayurveda. This article highlights how the bedside experience in arthritis has been translated by RP into evidence by defined experimental and clinical studies. There is a need to understand and apply the basic principles and practices of Ayurveda in the specific protocols and models in RP so as to truly integrate effective and safe usage for definite indications. The article also discusses the RP approach for Ayurvedic medicines used for treatment of arthritis.Keywords
Ayuveda, Integrative Medicine, Repurposing Drug, Reverse Pharmacology.Full Text
- Ayurveda Rasayana in Prophylaxis of Covid-19
Abstract Views :275 |
PDF Views:69
Authors
Bhushan Patwardhan
1,
Preeti Chavan-Gautam
2,
Manish Gautam
3,
Girish Tillu
2,
Arvind Chopra
4,
Sunil Gairola
3,
Suresh Jadhav
3
Affiliations
1 AYUSH Centre of Excellence, Centre for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune Univer-sity, Pune 411 007, IN
2 AYUSH Centre of Excellence, Centre for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune 411 007, IN
3 Serum Institute of India Ltd, Pune 411 028, IN
4 Centre for Rheumatic Diseases, Pune 411 001, IN
1 AYUSH Centre of Excellence, Centre for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune Univer-sity, Pune 411 007, IN
2 AYUSH Centre of Excellence, Centre for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune 411 007, IN
3 Serum Institute of India Ltd, Pune 411 028, IN
4 Centre for Rheumatic Diseases, Pune 411 001, IN
Source
Current Science, Vol 118, No 8 (2020), Pagination: 1158-1160Abstract
Respiratory viral infections such as SARS-CoV-2 affect immune homeostasis by altering the immune regulatory network leading to decreased responsiveness, changes in lymphocyte sub-populations and decreased macrophage function1 . Clinically, the immune response induced by SARS-CoV-2 infection occurs in two phases: the first immune defence-based protective phase and the second inflammation-driven damaging phase2 . The first immune defence-based protective phase is characterized by recruitment of antibody-secreting cells, follicular helper T-cells, activated CD4 and CD8 T-cells and immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies that bind to SARS-CoV-2 (ref.3). The second phase leads to uncontrolled cytokine release causing cytokine release syndrome (CRS), or ‘cytokine storm’ characterized by increased IL-2, IL-7, granulocyte colony stimulating factor, IFN-gamma and TNF-alpha4 . CRS damages tissues of the lungs, kidney and heart leading to rapid multiorgan failure. The deaths from COVID-19 are due to massive alveolar damage leading to acute respiratory distress syndrome (ARDS) that culminates in respiratory failure. Restoration of Th1/Th-2 cytokine balance is one of the mechanisms of establishing immune homeostasis5,6 .Full Text
References
- Zhou, Y. et al., Natl. Sci. Rev., 2020, nwaa041.
- Shi, Y. et al., Cell Death Differ., 2020.
- Thevarajan, I. et al., Nat. Med., 2020.
- Mehta, P. M., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S. and Manson, J. J., Lancet, 2020 (published online 16 March).
- Kidd, P., Altern. Med. Rev., 2003, 8(3), 223–246.
- Spellberg, B. and Edwards Jr, J. E., Clin. Infect. Dis., 2001, 32(1), 76–102.
- Yan, G. et al., Lancet Infect. Dis., 2020, S1473-3099(20)30158-4.
- Guo, X. J., Semin. Immunopathol., 2017, 39(5), 541–550.
- Ben-Zvi, I. et al., Clin. Rev. Allergy Immunol., 2012, 42(2), 145–153.
- Chopra, A., Saluja, M. and Venugopalan, A., Arthritis Rheum., 2014, 66(2), 319– 326.
- Liu, J. et al., Cell Discov., 2020, 6, 16.
- Chen, Z. et al., medRxiv, 2020.03.22.20040758
- Yazdany, J. and Kim, A. H., Ann. Inter.Med.. 31 March 2020, doi:10.7326/M20-1334.
- https://www.mohfw.gov.in/pdf/Advisory-ontheuseofHydroxychloroquinasprophy-laxisforSARSCoV2infection.pdf
- https://www.un.org/sustainabledevelop-ment/blog/2020/03/un-health-chief-announces-global-solidarity-trial-to-jumpstart-search-for-covid-19-treatment/
- Saggam. A. et al., J. Ethnopharmacol., 2020, 255, 112759.
- Chopra, A. et al., J. Rheumatol., 2000, 27, 1365–1372.
- Chopra, A., Saluja, M. and Tillu, G., J. Ayurveda Integr. Med., 2010, 1(3), 190– 198.
- Chopra, A. et al., J. Ayurveda Integr. Med., 2018, 9(3), 201–208.
- Chopra, A. et al., J. Ayurveda Integr. Med., 2012, 3(1), 38–44.
- Ritchie, A. I. and Singanayagam, A., Lancet, 2020, S0140–6736(20), 30691– 30697.
- Agarwal, R. et al., J. Ethnopharmacol., 1999, 67, 27–35.
- Diwanay, S., Chitre, D. and Patwardhan, B., J. Ethnopharmacol., 2004, 90, 49–55.
- Gautam, M. et al., J. Ethnopharmacol., 2009,121(2), 241–247.
- Gautam, M. et al., Int. Immunopharmacol., 2004, 4, 841–849.
- Patil D. et al., Integr. Cancer Ther., 2014, 13(2), 167–175.
- Patwardhan, B. and Gautam, M., Drug Discov. Today, 2005, 10(7), 495–502.
- Sumantran, V. N. et al., Phytother. Res., 2008, 22, 1342–1348.
- Sumantran, V. N., et al., J. Biosci., 2007, 32(2), 299–307.
- Bani, S. et al., J. Ethnopharmacol., 2006, 107, 107–115.
- Teixeira, S. T. et al., Int. Immunopharmacol., 2006, 6(10), 1535–1542.
- Ganguly, B. et al., Trop. Anim. Health Prod., 2019.
- Kumar, R. et al., Indian J. Tuberc., 2018, 65(3), 246–251.
- Patil, D. et al., Planta Med., 2010, 76, 481–488.
- Grandhi, A., Mujumdar, A. M. and Patwardhan, B., J. Ethnopharmacol., 1994, 44, 131–135.
- Patwardhan, B., Curr. Sci., 2012, 102(10), 1406–1417.
- Chan, K. W., Wong, V. T. and Tang, S. C. W., Am. J. Chin. Med., 2020, 1–26.
- TCM Clinical Studies registered in Chinese Clinical Trial Registry; http://www.chictr.org.cn(accessed on 29 March 2020).
- Luo, H. et al., Chin. J. Integr. Med., 2020, 1–8.
- Ren, J. L., Zhang, A. H. and Wang, X. J., Pharmacol. Res., 2020, 155, 104743.
- Yang, Y. and Zhang, T., BMJ, 2020, 368.